Alexion Reports Third Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Goldman Sachs Upgrades Alexion Pharmaceuticals (ALXN) to Buy
October 28, 2016 7:49 AM EDTGoldman Sachs upgraded Alexion Pharmaceuticals (NASDAQ: ALXN) from Neutral to Buy with a price target of $158.00.
For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $131.37 yesterday.
... MoreAlexion Pharma (ALXN) Tops Q3 EPS by 6c; Guides Relativity In-Line
October 27, 2016 6:35 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $1.23, $0.06 better than the analyst estimate of $1.17. Revenue for the quarter came in at $799 million versus the consensus estimate of $786.86 million.
GUIDANCE:
Alexion Pharma sees FY2016 EPS at upper end of $4.50-$4.65, versus... More
